869367-96-4

Basic information

• Product Name: (3R,4'S)-2-benzyl-5-bromo-3-(2',2'-dimethyl-1',3'-dioxolan-4'-yl)-4,4-dimethoxy-2,3,4,7-tetrahydro-1,2-oxazepine
• Synonyms: (3R,4'S)-2-benzyl-5-bromo-3-(2',2'-dimethyl-1',3'-dioxolan-4'-yl)-4,4-dimethoxy-2,3,4,7-tetrahydro-1,2-oxazepine
• CAS NO: 869367-96-4
• Molecular Weight: 428.323
• Mol File: 869367-96-4.mol

Chemical Properties

• CAS DataBase Reference: (3R,4'S)-2-benzyl-5-bromo-3-(2',2'-dimethyl-1',3'-dioxolan-4'-yl)-4,4-dimethoxy-2,3,4,7-tetrahydro-1,2-oxazepine(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4'S)-2-benzyl-5-bromo-3-(2',2'-dimethyl-1',3'-dioxolan-4'-yl)-4,4-dimethoxy-2,3,4,7-tetrahydro-1,2-oxazepine(869367-96-4)
• EPA Substance Registry System: (3R,4'S)-2-benzyl-5-bromo-3-(2',2'-dimethyl-1',3'-dioxolan-4'-yl)-4,4-dimethoxy-2,3,4,7-tetrahydro-1,2-oxazepine(869367-96-4)

Safety Data

• Hazardous Substances Data: 869367-96-4(Hazardous Substances Data)

Upstream product

• 227622-64-2 (3R,4'S)-2-benzyl-3-(2',2'-dimethyl-1',3'-dioxolan-4'-yl)-4-methoxy-3,6-dihydro-2H-1,2-oxazine 
• 869367-94-2 (5R,4'S)-4-benzyl-7,7-dibromo-5-(2',2'-dimethyl-1',3'-dioxolan-4'-yl)-6-methoxy-3-oxa-4-azabicyclo[4.1.0]heptane 
• 67-56-1 methanol 

Downstream Products

• 869368-04-7 (3R,4'S)-3-{2-benzyl-4,4-dimethoxy-3-(2',2'-dimethyl-1',3'-dioxolan-4'-yl)-2,3,4,7-tetrahydro[1,2]oxazepin-5-yl}acrylic acid methyl ester 

Relevant articles and documents

Ring enlargement of carbohydrate-derived 1,2-Oxazines to enantiopure 5-Bromo-1,2-oxazepines and subsequent palladium-catalyzed reactions

Dibromocarbene addition to d-glyceraldehyde-derived 1,2-oxazines syn-1 and anti-1 provided dibromocyclopropane intermediates syn-3 and anti-3, which smoothly reacted with methanol under ring enlargement to furnish 5-bromo-1,2-oxazepine derivatives syn-4 a

Ring enlargement of enantiopure 1,2-oxazines to 1,2-oxazepine derivatives and their palladium-catalyzed couplings

Phase-transfer-catalyzed cyclopropanation of enantiopure 1,2-oxazine derivatives anti-1a,b or syn-1 followed by solvolysis of the resulting geminal dibromocyclopropane intermediates afforded the expected ring-expanded products, namely 1,2-oxazepines anti-